Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response
Ok-Kyong Chaekal(NewYork–Presbyterian Hospital), Koen van Besien(University Hospitals of Cleveland), Maria S. Albano(New York Blood Center), Gail J. Roboz(Cornell University), Emeline Masson Frenet(New York Blood Center), Cynthia Romeo(New York Blood Center), Adrienne A. Phillips(Palmetto Hematology Oncology), Michael S. Samuel(Cancer Research UK Scotland Institute), Nina Orfali(St. James's Hospital), Usama Gergis(Thomas Jefferson University Hospital), Tsiporah B. Shore(Cornell University), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Ludy Dobrila(New York Blood Center), Andromachi Scaradavou(NewYork–Presbyterian Hospital), Jingmei Hsu(Cancer Research Institute), Sang‐Min Lee(Seoul National University), Danielle Guarneri(Palmetto Hematology Oncology), Sebastian Mayer(Mount Sinai Hospital), Melissa M. Cushing(NewYork–Presbyterian Hospital)
Cited by 5
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k